Journal List > J Korean Diabetes > v.12(4) > 1054799

TOOLS
Lee and Choi: Pharmacothearpy of Adolescents with Diabetes
Focused Issue

J Korean Diabetes 2011;12(4):211-214.

Published online: 22 January 2011

DOI: https://doi.org/10.4093/jkd.2011.12.4.211

Pharmacothearpy of Adolescents with Diabetes

Yenna Lee, Sung Hee Choi

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Copyright © 2011 Korean Diabetes Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Diabetes in adolescents is gaining importance since most type 1 diabetes onsets at young age, and the prevalence of type 2 diabetes is increasing in parallel with childhood obesity. Pharmacotherapy of adolescents with diabetes requires special attention because adolescence is characterized by physical and emotional growth due to a unique hormonal influence. However, a scarcity of data exists on this issue, and insulin and metformin remain as the mainstay of pharmacotherapy in adolescents with diabetes. More studies on the efficacy and safety of available medications are needed to advance pharmacotherapy in this unique population.

Keywords: Type 1 diabetes mellitus, Type 2 diabetes mellitus, Adolescent, Drug therapy, Insulin

REFERENCES

1. Incidence of diabetes. In: International Diabetes Federation. Diabetes Atlas. 3rd ed.Brussels: International Diabetes Federation;2006. p. 2.
2. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care. 2011; 34(Suppl 1):S11–61.
3. International Diabetes Federation. Global IDF/ISPAD guideline for diabetes in childhood and adolescence. Brussels: International Diabetes Federation Communications;2011. p. 54.
5. Särnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol. 2003; 149:323–9.
6. Gómez R, Mokhashi MH, Rao J, Vargas A, Compton T, McCarter R, Chalew SA. Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study. J Pediatr Endocrinol Metab. 2002; 15:1147–51.
crossref
7. Follansbee DS. Assuming responsibility for diabetes management: what age? What price? Diabetes Educ. 1989; 15:347–53.
crossref
8. Grey M, Boland EA, Yu C, Sullivan-Bolyai S, Tamborlane WV. Personal and family factors associated with quality of life in adolescents with diabetes. Diabetes Care. 1998; 21:909–14.
crossref
9. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, Laffel L, Deeb L, Grey M, Anderson B, Holzmeister LA, Clark N. American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care. 2005; 28:186–212.
10. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009; 52:17–30.
11. Sellers EA, Dean HJ. Short-term insulin therapy in adolescents with type 2 diabetes mellitus. J Pediatr Endocrinol Metab. 2004; 17:1561–4.
crossref
12. Zuhri-Yafi MI, Brosnan PG, Hardin DS. Treatment of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab. 2002; 15(Suppl 1):541–6.
13. Weigensberg MJ, Goran MI. Type 2 diabetes in children and adolescents. Lancet. 2009; 373:1743–4.
crossref
14. Type 2 diabetes in children and adolescents. American Diabetes Association. Diabetes Care. 2000; 23:381–9.
15. Rosenbloom AL, Silverstein JH, Amemiya S, Zeitler P, Klingensmith GJ. Type 2 diabetes in children and adolescents. Pediatr Diabetes. 2009; 10(Suppl 12):17–32.
crossref
16. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care. 2002; 25:89–94.
17. Berry D, Urban A, Grey M. Management of type 2 diabetes in youth (part 2). J Pediatr Health Care. 2006; 20:88–97.
crossref
18. Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007; 30:790–4.
19. TODAY Study Group. Zeitler P, Epstein L, Grey M, Hirst K, Kaufman F, Tamborlane W, Wilfley D. Treatment options for type 2 diabetes in adolescents and youth: a study of the comparative efficacy of metformin alone or in combination with rosiglitazone or lifestyle intervention in adolescents with type 2 diabetes. Pediatr Diabetes. 2007; 8:74–87.
crossref
20. Zdravkovic V, Hamilton JK, Daneman D, Cummings EA. Pioglitazone as adjunctive therapy in adolescents with type 1 diabetes. J Pediatr. 2006; 149:845–9.
crossref
21. Silverstein JH, Rosenbloom AL. Treatment of type 2 diabetes mellitus in children and adolescents. J Pediatr Endocrinol Metab. 2000; 13(Suppl 6):1403–9.
crossref
22. Flint A, Arslanian S. Treatment of type 2 diabetes in youth. Diabetes Care. 2011; 34(Suppl 2):S177–83.
crossref
23. Malloy J, Capparelli E, Gottschalk M, Guan X, Kothare P, Fineman M. Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. Clin Ther. 2009; 31:806–15.
crossref
24. Raman VS, Mason KJ, Rodriguez LM, Hassan K, Yu X, Bomgaars L, Heptulla RA. The role of adjunctive exenatide therapy in pediatric type 1 diabetes. Diabetes Care. 2010; 33:1294–6.
crossref
25. Elasy TA, Levy P, Davis SN. Optimizing combination therapy for type 2 diabetes in adolescents and adults: a case-based approach. J Fam Pract. 2004; 53:815–22.

Table 1.
Glycemic recommendations for adolescents with diabetes
Biochemical assessment ADA/APA 2011 IDF-ISPAD 2011
Fasting plasma glucose (mg/dL) 90-130 90-145
Postprandial plasma glucose (mg/dL) 90-180
Bedtime plasma glucose (mg/dL) 90-150 120-180
Hemoglobin A1C (%) ＜ 7.5a ＜ 7.5a

ADA, American Diabetes Association; APA, American Psychiatric Association; IDF, International Diabetes Federation; ISPAD, International Society for Pediatric and Adolescent Diabetes.

a Target hemoglobin A1C level may be lowered to 7.0% in the absence of hypoglycemia.

TOOLS
Similar articles